Cargando…
P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR-NAÏVE PNH PATIENTS
Autores principales: | Peffault de Latour, Régis, Han, Bing, Maciejewski, Jaroslaw P, Ueda, Yasutaka, Fu, Rong, Zhang, LI, Kulasekararaj, Austin, Röth, Alexander, Ping Chew, Lee, Ho Jang, Jun, Wong, Lily L L, Panse, Jens, Yap, Eng-Soo, Marano, Luana, Sicre de Fontbrune, Flore, Yang, Chen, Banerjee, Partha, Wang, Zhixin, Thorburn, Christine, LI, Shujie, Dahlke, Marion, Maria Risitano, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430477/ http://dx.doi.org/10.1097/01.HS9.0000970000.03386.8c |
Ejemplares similares
-
S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
por: Risitano, Antonio Maria, et al.
Publicado: (2023) -
PB2063: APPULSE-PNH: A PHASE IIIB TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) ON ANTI-C5 THERAPY WITH HEMOGLOBIN >10G/DL
por: Risitano, Antonio Maria, et al.
Publicado: (2023) -
Management of paroxysmal nocturnal hemoglobinuria (PNH)
por: Luzzatto, Lucio
Publicado: (2022) -
Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry
por: Schrezenmeier, Hubert, et al.
Publicado: (2020) -
Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry
por: Höchsmann, Britta, et al.
Publicado: (2023)